Analysts Set Progyny, Inc. (NASDAQ:PGNY) Price Target at $25.42

Shares of Progyny, Inc. (NASDAQ:PGNY) have been given a consensus rating of “Hold” by the thirteen research firms that are currently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.42.

A number of research firms recently commented on PGNY. JMP Securities lowered shares of Progyny from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 19th. Truist Financial restated a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Leerink Partners lowered their price target on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a report on Thursday, September 19th. Jefferies Financial Group lowered their price target on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, September 19th. Finally, Bank of America lowered their price target on shares of Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Progyny Price Performance

NASDAQ PGNY opened at $13.67 on Friday. The firm has a market capitalization of $1.16 billion, a PE ratio of 23.57, a P/E/G ratio of 1.44 and a beta of 1.44. Progyny has a 12 month low of $13.39 and a 12 month high of $42.08. The company’s 50 day simple moving average is $16.92 and its 200 day simple moving average is $22.98.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.16 earnings per share. Sell-side analysts anticipate that Progyny will post 0.64 earnings per share for the current fiscal year.

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. Quarry LP grew its stake in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after buying an additional 836 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Progyny during the second quarter worth about $44,000. Cambridge Trust Co. bought a new stake in Progyny during the first quarter worth about $95,000. Natixis Investment Managers International bought a new stake in Progyny during the first quarter worth about $117,000. Finally, Mendota Financial Group LLC bought a new stake in Progyny during the third quarter worth about $56,000. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.